CA-GIANT-PROTOCOL
27.1.2022 16:25:07 CET | Business Wire | Press release
GIANT Protocol, a leading-edge web3 protocol building a decentralized connectivity economy, today announced the release of its Litepaper, laying out the various components of GIANT Protocol’s ambitious proposal to decentralize and democratize access to the internet and financial services through a web3 telecommunications layer. GIANT plans to roll out the first iteration of its mainnet in the first half of 2022, so the publication of the Litepaper marks a critical step in ensuring GIANT Protocol’s commitment to being an open-source, public protocol built to support a globally connected world.
GIANT Protocol made its debut in November 2021, announcing its intention to build a tokenized bandwidth platform that will allow anyone with a mobile phone to access the internet and earn rewards based on their connectivity. With a founding team well-established in the telecom sector, GIANT Protocol intends to leverage existing network providers, allowing it to rapidly scale its network.
In December 2021, GIANT Protocol announced it had successfully raised $5 million in a seed funding round led by leading blockchain investment firm CoinFund. Now, the project is pleased to build on this progress with the publication of the Litepaper.
The Litepaper was co-authored by Suruchi Gupta, Founder, and CEO of Giant Protocol, along with the GIANT team. Speaking of its publication, Ms. Gupta commented: “The GIANT Litepaper lays out in detail the context and strategy for building a global telecommunications network that can deliver the benefits of web3 to everyone. We want it to convey our ultimate vision for GIANT: to make internet access more than a boring utility, transforming it into an exciting opportunity for better, faster, and more accessible internet access and accompanying financialization potential.”
Along with contextualizing the need for a global decentralized connectivity economy, the Litepaper provides an overview of GIANT’s proposal for its core connectivity infrastructure. It also outlines the GIANT tokenomic model and explains the DAO governance structure that will manage the protocol, including the role of the GIANT Protocol Foundation, a non-profit organization dedicated to supporting the protocol.
Finally, it shows what to expect from the first implementation of the GIANT Protocol – a wallet, a consumer software for end users to interact with GIANT, a provider software for network providers to offer internet access via GIANT, and a validator node software.
GIANT Protocol now invites feedback on the Litepaper from interested stakeholders who wish to be involved in the development and adoption of the GIANT Protocol, whether they’re network owners, developers, or data consumers.
To view the Litepaper, please visit https://giantprotocol.org/litepaper/
About GIANT Protocol
GIANT Protocol was founded in 2021 to decentralize and democratize access to the internet and financial services by tokenizing bandwidth. The project partners with telecommunications and connectivity providers across the globe to create a decentralized connectivity economy, allowing anyone with a mobile phone to participate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005732/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom